Status:
COMPLETED
Genetic Factors of the Desmopressin Response in Carriers of Hemophilia A
Lead Sponsor:
Groupe Maladies hémorragiques de Bretagne
Conditions:
Carrier of Hemophilia A
Desmopressin
Eligibility:
FEMALE
2-80 years
Brief Summary
Hemophilia A (HA) is a rare X-linked bleeding disorder caused by a deficiency in factor VIII (FVIII) affecting 1/5,000 males1. Carriers of HA are females carrying the pathogenic variant responsible fo...
Detailed Description
The GIDEHAC study is a French observational, retrospective, and multicentric study performed in carriers of hemophilia A of any age who have received the intravenous desmopressin in their French Hemop...
Eligibility Criteria
Inclusion
- Females at any ages with a formal diagnosis of HA carriers based on the F8 genetics,
- Patients having received DDAVP during the last 10 years that was associated with dosages of FVIII before and just after DDAVP,
- Factor VIII levels measurements realized at least 2 times during the therapeutic test, just before the DDAVP infusion and 30 or 60 minutes after.
Exclusion
- Patients with an anti-factor VIII inhibitor,
- Refusal to participate in the study,
- Unable to understand the study's French letter of non-opposition and information
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2023
Estimated Enrollment :
361 Patients enrolled
Trial Details
Trial ID
NCT06020456
Start Date
January 1 2022
End Date
April 1 2023
Last Update
August 31 2023
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
University hospital of Bordeaux
Bordeaux, France, 33604
2
University hospital of Brest
Brest, France, 29609
3
Hospices civils de Lyon
Bron, France, 69677
4
University hospital of Dijon
Dijon, France, 21079